List view / Grid view
24 March 2014 | By AbbVie
AbbVie will present new data from its phase III hepatitis C development program at the 2014 International Liver Congress™...
20 March 2014 | By GlaxoSmithKline
GSK will continue the trial in order to assess the third co-primary endpoint, which is disease-free survival in a gene signature positive sub-population...
20 March 2014 | By AbbVie
AbbVie announced the initiation of a pivotal Phase 3 clinical trial that will evaluate the use of HUMIRA® (adalimumab)...
19 March 2014 | By Janssen
Additional Phase 3 data from the QUEST-1, QUEST-2 and PROMISE studies explore potential of simeprevir in genotype 1 hepatitis C patients while new ATTAIN data demonstrate a superior safety profile for simeprevir...
19 March 2014 | By Sanofi
Sanofi Pasteur announced a long-term strategic cooperation with SK Chemical Co. to co-develop an innovative pneumococcal conjugate vaccine...
19 March 2014 | By Daiichi Sankyo
Astellas Pharma Inc. and Daiichi Sankyo Company, Limited announced the companies would form a compound library sharing partnership for approximately 400,000 selected compounds...
17 March 2014 | By Amgen
Study meets primary endpoint of LDL cholesterol reduction First phase 3 data of a pcsk9 inhibitor in patients with homozygous familial hypercholesterolemia - a rare and serious disease...
17 March 2014 | By Bristol-Myers Squibb
Five Prime Therapeutics, Inc. and Bristol-Myers Squibb Company announced that they have signed a collaboration agreement for the discovery, development and commercialization of immuno-oncology therapies...
13 March 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced that a pivotal phase III study of mepolizumab, an investigational IL-5 antagonist monoclonal antibody, met its primary endpoint of reduction in the frequency of exacerbations...
12 March 2014 | By Amgen
Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc., announced that a Phase 3 trial evaluating the investigational use of NEXAVAR® (sorafenib) tablets as an adjuvant treatment for patients with hepatocellular carcinoma...
12 March 2014 | By Sanofi
Sanofi and UCB announce they have entered into a scientific and strategic collaboration for the discovery and development of innovative anti-inflammatory small molecules...
7 March 2014 | By Novartis
Novartis announced that a pivotal Phase III trial of Jakavi® (ruxolitinib) compared to best available therapy has met its primary endpoint of maintaining hematocrit control...
6 March 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company presented 24-week Phase IIb data that demonstrated similar response rates for its investigational compound...
5 March 2014 | By Roche
Roche presented new data from the LUTE / VERSE phase IIb studies investigating lebrikizumab in patients with severe uncontrolled asthma...
5 March 2014 | By Merck
MSD announced results from a Phase 2b study evaluating two doses of its investigational house dust mite sublingual immunotherapy tablet (MK-8237)...
